潰瘍性大腸炎市場：薬剤、疾患、投与経路別-世界予測2025-2030年

潰瘍性大腸炎市場は、2023年に74億5,000万米ドルと評価され、2024年には81億4,000万米ドルに達すると予測され、CAGR 9.41％で成長し、2030年には139億9,000万米ドルに達すると予測されています。

潰瘍性大腸炎（UC）は慢性炎症性腸疾患で、主に結腸の最も内側の炎症が関与しています。UCがヘルスケア市場に与える影響は大きく、有病率の増加により効果的な治療と管理戦略が必要とされています。UCに対処する必要性は、食習慣の変化、ストレス、遺伝、環境的誘因などの要因によって、その有病率が増加していることにあります。このため、診断や管理のための医療機器の進歩とともに、生物学的製剤、バイオシミラー、低分子を含む新規治療薬への需要が高まっています。最終用途分野には、主に消化器疾患に焦点を当てた病院、診療所、研究機関が含まれ、患者の転帰とQOLの向上を目指しています。同市場の成長に影響を与える主な要因としては、高齢化、診断方法の向上、製品の技術革新が挙げられます。最近の個別化医療や標的治療の動向は、治療効果や患者のアドヒアランスを向上させる可能性のある免疫療法や遺伝子編集技術における画期的なブレークスルーによって強調され、大きなビジネスチャンスをもたらしています。こうした有望な動向にもかかわらず、市場は、高額な治療費、新興経済諸国における限られた認知度、新規開発と商業化を阻害しかねない厳しい規制承認プロセスなどの制約に直面しています。さらに、副作用や薬剤耐性に関する課題が現在も続いているため、継続的な調査と技術革新が必要となっています。イノベーションに最適な分野としては、非侵襲的診断ツールの開発、生物製剤とバイオシミラーの進歩、患者モニタリングと医薬品開発におけるAIの統合などが挙げられます。医薬品開発のための戦略的パートナーシップの構築、プレシジョン・ヘルス・ソリューションの研究育成、患者教育イニシアティブへの投資などに、事業成長の見込みがあります。UC市場の性質はダイナミックで急速に進化しており、技術の進歩や患者中心のケアへの重点の高まりに後押しされているため、利害関係者は新たな機会を見極めるために適応力と積極性を維持することが極めて重要です。

市場力学：急速に進化する潰瘍性大腸炎市場の主要市場インサイトを公開

潰瘍性大腸炎市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の潰瘍性大腸炎罹患率の上昇
  • ヘルスケア施設の充実と医薬品開発セクターの発展
  • 患者支援プログラムおよび償還政策の利用可能性
• 市場抑制要因
  • 原材料コストの変動
• 市場機会
  • 新薬製造のための継続的研究開発
  • 生物製剤の研究に対する公的機関および民間機関の関与の増加
• 市場の課題
  • バイオシミラーの承認における政府の厳しい規制

ポーターの5つの力：潰瘍性大腸炎市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：潰瘍性大腸炎市場における外部からの影響の把握

外部マクロ環境要因は、潰瘍性大腸炎市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析潰瘍性大腸炎市場における競合情勢の把握

潰瘍性大腸炎市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス潰瘍性大腸炎市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、潰瘍性大腸炎市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨潰瘍性大腸炎市場における成功への道筋を描く

潰瘍性大腸炎市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に潰瘍性大腸炎の発生率が上昇
    • ヘルスケア施設の充実と医薬品開発部門の発展
    • 患者支援プログラムと払い戻しポリシーの利用可能性
  • 抑制要因
    • 原材料費の変動
  • 機会
    • 新薬生産における継続的な研究開発
    • 生物製剤の調査への公的機関および民間組織の関与の増加
  • 課題
    • バイオシミラーの承認に関する政府の厳格な規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 潰瘍性大腸炎市場薬物別

• 抗炎症薬
• 抗TNF生物学的製剤
• カルシニューリン阻害剤
• 免疫抑制剤

第7章 潰瘍性大腸炎市場：疾患別

• 劇症大腸炎
• 左側大腸炎
• 全大腸炎または汎発性大腸炎
• 直腸S状結腸炎
• 潰瘍性直腸炎

第8章 潰瘍性大腸炎市場：投与経路別

• 注射可能
• オーラル

第9章 南北アメリカの潰瘍性大腸炎市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の潰瘍性大腸炎市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの潰瘍性大腸炎市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• BioLineRx Ltd
• Boehringer Ingelheim GmbH
• Celgene Corporation
• Circle33, LLC
• Cosmo Pharmaceuticals NV
• Eli Lilly and Company
• GlaxoSmithKline Plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Pfizer Inc.
• Sanofi SA

LIST OF FIGURES

• FIGURE 1. ULCERATIVE COLITIS MARKET RESEARCH PROCESS
• FIGURE 2. ULCERATIVE COLITIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ULCERATIVE COLITIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ULCERATIVE COLITIS MARKET DYNAMICS
• TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 50. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. INDIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 105. ITALY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 117. POLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 120. QATAR ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2023

The Ulcerative Colitis Market was valued at USD 7.45 billion in 2023, expected to reach USD 8.14 billion in 2024, and is projected to grow at a CAGR of 9.41%, to USD 13.99 billion by 2030.

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease that primarily involves inflammation of the colon's innermost lining. Its impact on the healthcare market is substantial, with a growing prevalence that necessitates effective treatments and management strategies. The necessity of addressing UC lies in its increasing prevalence, driven by factors such as changing dietary habits, stress, genetics, and environmental triggers. This has intensified the demand for novel therapeutics, including biologics, biosimilars, and small molecules, alongside advancements in medical devices for diagnostics and management. Application and end-use sectors primarily include hospitals, clinics, and research institutes focusing on gastrointestinal diseases, aiming to enhance patient outcomes and quality of life. Key factors influencing growth in this market include an aging population, better diagnostic methods, and incremental product innovations. Recent developments in personalized medicine and targeted therapies offer substantial opportunities, underscored by revolutionary breakthroughs in immunotherapies and gene editing technologies which can potentially improve treatment efficacy and patient adherence. Despite these promising trends, the market faces limitations such as high treatment costs, limited awareness in emerging economies, and stringent regulatory approval processes that can stifle new development and commercialization. Furthermore, ongoing challenges with side effects and drug resistance necessitate continuous research and innovation. The best areas for innovation include the development of non-invasive diagnostic tools, advancements in biologics and biosimilars, and the integration of AI in patient monitoring and drug development. Prospects of business growth lie in forging strategic partnerships for drug development, cultivating research in precision health solutions, and investing in patient education initiatives. The nature of the UC market is dynamic and rapidly evolving, driven by technological advancements and a growing emphasis on patient-centric care, making it crucial for stakeholders to remain adaptive and proactive in identifying emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ulcerative Colitis Market

The Ulcerative Colitis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of ulcerative colitis globally
  • Robust availability of healthcare facilities and evolving drug development sector
  • Availability of patient assistance programs and reimbursement policies
• Market Restraints
  • Fluctuating cost of raw materials
• Market Opportunities
  • Ongoing research and development in the production of novel drugs
  • Increasing public and private organization involvement in research of biologics
• Market Challenges
  • Strict government mandates in approval of biosimilars

Porter's Five Forces: A Strategic Tool for Navigating the Ulcerative Colitis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ulcerative Colitis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ulcerative Colitis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ulcerative Colitis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ulcerative Colitis Market

A detailed market share analysis in the Ulcerative Colitis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ulcerative Colitis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ulcerative Colitis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ulcerative Colitis Market

A strategic analysis of the Ulcerative Colitis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ulcerative Colitis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation, Circle33, LLC, Cosmo Pharmaceuticals NV, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Ulcerative Colitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors, and Immunosuppressant.
• Based on Disease, market is studied across Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis, Proctosigmoiditis, and Ulcerative Proctitis.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of ulcerative colitis globally
    • 5.1.1.2. Robust availability of healthcare facilities and evolving drug development sector
    • 5.1.1.3. Availability of patient assistance programs and reimbursement policies
  • 5.1.2. Restraints
    • 5.1.2.1. Fluctuating cost of raw materials
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and development in the production of novel drugs
    • 5.1.3.2. Increasing public and private organization involvement in research of biologics
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government mandates in approval of biosimilars
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Ulcerative Colitis Market, by Drug

• 6.1. Introduction
• 6.2. Anti-Inflammatory Drugs
• 6.3. Anti-TNF Biologics
• 6.4. Calcineurin Inhibitors
• 6.5. Immunosuppressant

7. Ulcerative Colitis Market, by Disease

• 7.1. Introduction
• 7.2. Fulminant Colitis
• 7.3. Left-Sided Colitis
• 7.4. Pancolitis or Universal Colitis
• 7.5. Proctosigmoiditis
• 7.6. Ulcerative Proctitis

8. Ulcerative Colitis Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral

9. Americas Ulcerative Colitis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Ulcerative Colitis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Ulcerative Colitis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. AstraZeneca PLC
• 4. Bausch Health Companies Inc.
• 5. BioLineRx Ltd
• 6. Boehringer Ingelheim GmbH
• 7. Celgene Corporation
• 8. Circle33, LLC
• 9. Cosmo Pharmaceuticals NV
• 10. Eli Lilly and Company
• 11. GlaxoSmithKline Plc
• 12. Johnson & Johnson Services, Inc.
• 13. Merck & Co., Inc.
• 14. Mitsubishi Tanabe Pharma Corporation
• 15. Pfizer Inc.
• 16. Sanofi SA